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Satellite cells are rare mononuclear skeletal muscle-resident cells that are the chief contributors to regenerative
myogenesis following muscle injury. Although first identified more than 50 years ago, it is only recently that the
murine satellite cell has become molecularly defined with the ability to prospectively isolate these cells from their
niche. Human satellite cells are considerably less well understood with relatively few studies having been
performed on them. In this review, a critical evaluation of this literature is provided along with a discussion of the
practical and methodological issues involved with research on human satellite cells. The therapeutic potential of
these and other cells types is also discussed, and the various challenges that face satellite cell therapy are
addressed.
Keywords: Stem cell, Satellite cell, Pax7, Therapy, Muscular dystrophyIntroduction
When Alex Mauro coined the term ‘satellite cell’ more
than 50 years ago, his tentative and humble suggestions
that these cells ‘indeed might be of interest to students
of muscle histology’ and ‘might be pertinent to the ve-
xing problem of skeletal muscle regeneration’ [1] belied
not only their immense interest to a wide range of biolo-
gists but also their preeminent status as the key contri-
butors to adult muscle regeneration. Satellite cells are
mononuclear cells with low cytoplasmic content that are
located between the basal lamina and sarcolemma of
adult skeletal muscle fibers [1]. Under normal condi-
tions, these cells are mitotically quiescent and in re-
sponse to injury become activated, proliferate and
differentiate into myocytes that eventually fuse with each
other or with existing myofibers to generate new muscle
tissue [2]. At least a portion of the satellite cell pool is
able to self-renew and is, therefore, considered a popula-
tion of bona fide stem cells. The ability of these cells to
self-renew and form new muscle tissue offers tremen-
dous therapeutic opportunity in conditions of muscle
disease or loss.
While our understanding of murine satellite cell biol-
ogy is rapidly expanding, human satellite cells are con-
siderably less well understood, with relatively few studies* Correspondence: andrew.n.billin@gsk.com
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distribution, and reproduction in any mediumhaving been performed on them (see Table 1). The
human satellite cell literature is also riddled with impre-
cise and, hence, confusing nomenclature. For the pur-
poses of this review, the term ‘satellite cell(s)’ is taken to
represent the total population of sublaminar/sarco-
lemma-adjacent cells. The prospective isolation techni-
ques in general use are assumed to isolate a portion of
this total population, although it is difficult to determine
experimentally the precise fraction of total satellite cells
isolated. Further, subsets of the population are divided
into satellite stem cells (predominantly self-renewing)
and satellite muscle progenitor cells (predominantly pro-
ducing myoblasts) [3]. With respect to these definitions
and considerable published literature, we suggest that
satellite cells in culture begin to exit the quiescent state
soon after seeding producing mostly myogenic progeni-
tors and rarely dividing to self-renew. Therefore, such
cultures are more appropriately termed satellite cell
initiated cultures [4,5].Satellite cells and muscle regeneration
Satellite cells display a marked decrease in number from
birth onwards. Electron microscopy revealed that in
mice satellite cell nuclei account for 30% to 35% of total
myofiber nuclei at birth but less than 5% in adult muscle
[6]. Similar values have been obtained for human adult
muscle (4%, 4.4%, and 2% [7-9]). Although actively con-
tributing to muscle growth in juveniles [10], satellite
cells are present in a quiescent state in adult muscletral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Comparison of murine and human satellite cells
Category Mouse Human
Identifiable on muscle sections? Yes By EM [6] By IHC; markers include Pax7 [21]
and M-cadherin [22]
Yes By EM [7] By IHC; markers include Pax7
and CD56 [24]
Isolation of myofiber with associated satellite cells? Yes [27] Yes [26]
Identify live cells in culture?a Yes [17,33-36] Yes [61,62]
Intramuscular abundance Less than 5% [6] about 2% [9]; about 4% [7,8]
Gene signatures of satellite cells?a Yes [63,64] Yes [65]
Contribution to muscle growth following
transplantation?
Yes [18,19,66] ?
Formation of functional satellite cells in vivo
following transplantation?
Yes [18,19,66] ?
Satisfy criteria for being bona fide stem cells? Yes [3,17] ?
aAlthough the authors of all the cited papers refer to their isolated cells as ‘satellite cells’, this designation is often not the same as the definition used here. Please
refer to the main text for a detailed discussion. EM, electron microscopy; IHC, immunohistochemistry.
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escence in response to exercise [12], muscle stretch
[13,14] and injury [15]. Once activated, satellite cells fol-
low a well-characterized proliferation and differentiation
pathway, and have been shown to completely regenerate
new myofibers within four days [16]. Although other cell
types display varying degrees of myogenic potential (dis-
cussed later in this review), satellite cells are the only
muscle-resident cell population to exhibit all of the
properties of fully myogenic muscle stem and progenitor
cells, including robust myofiber regeneration in injured
muscle and engraftment of the satellite cell compart-
ment following intramuscular injection [5,17-19].
Identification and isolation of satellite cells
The discovery and early identification of satellite cells
was made possible by the use of electron microscopy [1],
which is a method that is still used today to reveal ultra-
fine structural details [20]. The next breakthrough in our
understanding of the satellite cell compartment came
with the use of immunohistochemistry on muscle sec-
tions to visualize characteristic expression markers with
fluorescence microscopy. These studies uncovered pro-
teins enriched in the satellite cell associated with puri-
fied fibers such as Pax7 [21], CD34 [22], and specifically
in humans, CD56 [23] among many other markers
(reviewed extensively in [2]). It has become routine for
these stains to be performed along with antibodies to
laminin, which is a constituent of the basal lamina that
surrounds each muscle fiber and allows for the correct
identification of satellite cells as residing underneath the
basal lamina [24] (Figure 1). Given that such tools and
techniques are in general use, human satellite cells can
be readily identified in tissue sections [8] and by flow
cytometry of muscle derived fixed cell suspensions [25].
Intact, isolated single fiber staining has also been used
to identify human satellite cells in much the same wayas mouse satellite cells have been identified in this
preparation. This technique has recently been used to
identify satellite cells on human myofibers isolated
from biopsies [26].
Despite the availability of numerous histological mar-
kers, the correct isolation of a pure population of human
satellite cells has remained elusive. Skeletal muscle is a
heterogeneous mix of cell populations which makes con-
tamination of heterologous stem cells a difficult problem
to circumvent. Additionally, studies claiming to have iso-
lated human satellite cells have lacked sufficient experi-
mental demonstration of the isolated cells’ properties.
We believe that in order for a cell population to qualify
as genuine satellite cells, the following in vitro and
in vivo experimental tests must be satisfied. In vitro, they
must be able to form myogenic colonies when cloned as
single cells and form myogenic cultures when cultured
en masse; 2) upon transplantation into the muscle envir-
onment they must contribute to new muscle formation
in vivo; 3) upon transplantation they must occupy the
satellite cell niche in vivo and expand over time in the
niche; and 4) post-transplantation they must be able to
undergo re-isolation from host muscle and still fulfill the
above criteria.
Popular methods of isolating satellite cells include the
removal and culturing of individual myofibers that har-
bor satellite cells, enzymatic or non-enzymatic liberation
of satellite cells from muscle tissue and fluorescence-
activated cell sorting (FACS) of satellite cells using spe-
cific cell-surface markers. Richard Bischoff developed
the technique of isolating and culturing individual myo-
fibers from rat flexor digitorum muscle. Scanning elec-
tron micrographs of these myofibers clearly revealed the
presence of attached satellite cells [27]. This method has
since been used on other skeletal muscles [28-30]. An
obvious limitation of the use of this method to study




Figure 1 Satellite cell in cross-section of human myofiber. A: Hoechst 33342 staining indicating nucleus. B: Pax7 staining indicating satellite
cell. C: Lamin A/C staining indicating nuclear membrane surrounding the satellite cell. D: Laminin staining indicating basal lamina surrounding
the myofiber. E: Composite of images A to D.
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lated and cultured.
Pre-plating and differential centrifugation are two
methods of isolating satellite cells from muscle derived
cell suspensions. Following the physical and enzymatic
breakdown of muscle tissue, pre-plating is used to obtain
an enriched population of satellite cells by removing
fibroblasts that adhere more strongly to the plastic in
tissue culture flasks than do satellite cells. The major
disadvantage of both these techniques is that they do
not guarantee an entirely pure population of satellite
cells [31]. Also, as satellite cells typically become acti-
vated soon after isolation, thereby losing much of their
therapeutic regenerative potential [32], use of this tech-
nique is inappropriate for isolating quiescent satellite
cells as it typically takes many days to perform.
The most sophisticated method currently being used
to isolate satellite cells is FACS. Knowledge of satellite
cell-specific surface markers has been exploited by using
fluorochrome-conjugated antibodies to discriminate and
separate these cells from others following enzymatic and
physical breakdown of muscle tissue. The most success-
ful methods make use of antibodies that bind to both
positive (proteins specific to satellite cells) and negative
(proteins that are expressed by contaminant cells) mar-
kers. Different groups have used different combinations
of markers, with comparable results from mouse muscle.
For example, the marker sets CXCR4+, β1-integrin+,CD45-, Sca1-, Mac1-; α7-integrin+, CD34+, CD45-, CD31-,
CD11b-, Sca1-; and α7-integrin+, CD45-, CD31-, Sca1-
have all been used to isolate pure populations of cells
that display the morphological and phenotypic prop-
erties of satellite cells and that regenerate damaged
muscle tissue when injected into mouse muscle
[17,33,34]. In addition, some investigators have used
VCAM1 and Syndecan3/4 antibodies in combination
with the negative selection markers listed above for
the prospective isolation of murine satellite cells
[35,36]. Antibodies against Pax7 have been used to
isolate satellite cells from human muscle biopsies
[25]. However, as Pax7 is an intracellular protein, it
cannot be used to isolate live satellite cells.
Pisani et al. have demonstrated the power of this tech-
nique by showing that even a single marker (CD34) can
be used to separate cells derived from human muscle bi-
opsies with myogenic potential (CD34-) from cells with
adipogenic potential (CD34+). In addition to deepening
our understanding of the different cell types that reside
in human skeletal muscle, this finding is of therapeutic
value as it might be desirable to eliminate cell types with
adipogenic potential when performing cell therapy for
treating muscle diseases, such as Duchenne muscular
dystrophy (DMD), which result in harmful fat accumula-
tion [37]. However, it must be noted here that so-called
fibro/adipogenic progenitors have been shown to have
pro-myogenic effects on satellite cells in the mouse, and
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The FACS technique has been used by Pisani et al. to
identify a rare population of multipotent adipomyogenic
cells (CD34+CD15+CD56+) that can give rise to com-
mitted adipogenic (CD34+CD15+CD56-) and myogenic
(CD34+CD15-CD56+) progenitors. These multipotent
progenitors are located in the interstitial compartment
and do not express Pax7, so are, therefore, distinct from
satellite cells [40]. Nevertheless, these promising findings
suggest that we are close to establishing a set of surface
markers that can be used to prospectively isolate a pure
population of human satellite cells. The identification of
such a set of antibody markers will, however, not suffice
to declare that the isolated cells are satellite cells. As in
the mouse system, the isolated cells must have the func-
tional properties of a satellite cell. Complicating these
experiments will be the need to rely on immunocom-
promised mice as hosts for the cells and lack of genetic
cell fate markers as have been used in mice.
The isolation of human satellite cells will allow for the
first time a direct side-by-side comparison with mouse
satellite cells. While it is generally assumed that mouse
and human satellite cell biology is congruent, there is
currently little direct experimental evidence supporting
this assumption.
Therapeutic opportunity of satellite cells
The chronic and debilitating loss of muscle function is a
problem that afflicts many people. Loss of function can
be the result of atrophy (which refers to the reduction of
muscle mass of genotypically normal muscle, of which
there can be many causes) or dystrophy (which in the
context of muscle physiology refers to loss of functional
muscle caused, usually, by a genetic defect). A third kind
of muscle function loss may be the result of traumatic
injury that damages large sections of muscle called volu-
metric muscle loss [41]. Two major types of atrophy are
cachexia and sarcopenia. Cachexia is a multifactorial
syndrome that involves the sudden loss of body fat and
muscle as the result of disease (such as cancer or AIDS),
while sarcopenia is defined as age-related muscle loss
[42]. Of the many muscular dystrophies identified, DMD
is one of the most severe and the most common. DMD
is an X-linked recessive disease that afflicts 1 in every
3,300 boys and is caused by the absence of the protein
dystrophin. It is a severely debilitating disease with many
patients dying of respiratory failure in their twenties
[43]. Muscle loss due to trauma is a much more diffuse
group of syndromes but still very debilitating for those
suffering from such injuries. In terms of therapeutic
approaches invoking the activity of satellite cells the
muscular dystrophies and traumatic injuries are more
likely to benefit than atrophy conditions because the
former are diseases or conditions in which regenerationof muscle tissue is compromised or insufficient. In fact,
recent studies suggest that satellite cell activity may not
be needed for certain kinds of muscle hypertrophy, fur-
ther casting doubt on the potential efficacy of therapies
for atrophy aimed at increasing the activity of satellite
cells [44,45].
Of the many therapeutic strategies that are currently
being tested to combat muscular dystrophy and to pro-
mote muscle regeneration, cell therapy is an approach
that has received much attention and shows promise.
This strategy involves the delivery of cells that make
new muscle to diseased areas. These can either be
muscle precursor cells or stem cells that have the ability
to differentiate into muscle cells. Myoblast transfer
(MT) is the oldest cell therapy approach and involves
the derivation of myoblast cells from healthy donor skel-
etal muscle, expansion of these cells in culture, and ad-
ministration to dystrophic tissue. Despite initially
promising results, this approach has been plagued by
many problems, namely poor migration of these cells
and the need for immunosuppressants, which could have
toxic effects and actually kill the myoblasts themselves
[46]. There is, therefore, clearly a need to find an alter-
native type of cell, which has more potent myogenic
effects. Ideally, this cell type would also have the ability
to self-renew. Satellite cells are an ideal candidate as
they not only have the ability to generate new muscle ef-
fectively but are also able to create new copies of them-
selves [17,32].
Therapeutic challenges for satellite cell therapy
Establishing a reliable method of isolating a pure popula-
tion of human satellite cells is only the first step towards
developing a therapy for muscle disease. Among the
many hurdles that need to be circumvented is the pro-
duction of a sufficient number of cells for an effective,
whole-body therapy. Satellite cells are rare, accounting
for less than 5% of total myofiber nuclei in humans [8].
This problem is compounded by the fact that muscle bi-
opsies tend to be very small. There is currently debate
about the minimum number of cells needed for an ef-
fective therapy. There is evidence that significantly fewer
satellite cells are needed to regenerate muscle tissue
compared to myoblasts. Remarkably, transplantation of
even one satellite cell is sufficient to give rise to new
myofibers and satellite cells [5]. Despite this impressive
finding, it is very likely that many more satellite cells will
be required as multiple muscle groups will need to be
targeted in patients. Unfortunately, ex vivo expansion of
murine satellite cells significantly impairs in vivo engraft-
ment potential following transplantation [32]. Therefore,
a major challenge is to increase the number of satellite
cells in culture while ensuring that they retain their po-
tent regenerative and self-renewal properties. Further
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maintenance of stem cell regenerative and self-renewal
properties in vitro.
The term ‘niche’ refers to a restricted, complex milieu
that impinges on stem cell survival and function. It
refers to anatomical position and biophysical properties
associated with that position, signaling molecules (such
as mitogens, myokines and growth factors) and sur-
rounding cells and tissue. A pivotal series of experiments
was performed by Carlson and Faulkner, who showed
that when limb muscles from old rats were transplanted
into the limbs of young mice they displayed significant
improvement in mass and force production compared to
muscle transplanted into old hosts, thereby highlighting
the importance of the muscle environment to muscle
maintenance and function [47]. It has since been shown
that aged satellite cells possess the latent ability to effect-
ively proliferate and regenerate muscle, which can be
reawakened after exposure to FGF (fibroblast growth
factor) [29] and serum from young mice [48]. In
addition to local biochemical influences, satellite cells
have also been shown to be affected by the physical
properties of the surrounding tissue. Ex vivo experi-
ments on freshly-obtained satellite cells have revealed
that their proliferative capacity is influenced by the elas-
ticity of the substrate on which they are cultured, while
their ability to differentiate is influenced by both elasti-
city and substrate protein composition [49]. Of note is a
recent study that reveals the surprising finding that
muscle stem cells are enriched in post-mortem tissue,
thus revealing another potential source of satellite cells
that could be of therapeutic use [50].
Another possible therapeutic challenge is immune re-
jection of transplanted allogeneic cells and/or resulting
myofibers. This is a problem that has hampered many
myoblast transfer trials and has necessitated the use of
immunosuppressants. A recent study highlights dramatic
levels of immune rejection following intramuscular in-
jection of myoblasts into macaques. The authors suggest
that sarcolemmal damage is caused by the infiltration of
CD8+ lymphocytes [51]. However, Hall et al. have
shown that the delivery of as few as three to five myofi-
bers (with resident satellite cells attached) to immuno-
competent mouse tissue results in long-term (up to 21
months) engraftment and tissue regeneration [18]. Al-
though the authors do not provide an explanation for
why the foreign tissue was not rejected, this is nonethe-
less a promising result that warrants further research.
Another potentially confounding issue is that of het-
erogeneity of satellite cells, which has been extensively
reviewed elsewhere [52]. In mice, approximately 10% of
satellite cells have never expressed the myogenic factor
Myf5, and these have been termed ‘satellite stem cells’
because they have more potent engraftment potentialand ability to self-renew than Myf5+ cells [3]. It is,
therefore, imperative that similar studies be performed
in humans to possibly identify a sub-population of satel-
lite cells that are more therapeutically relevant.
Therapeutic potential of other cell types
In mice, many other cell types, both within and without
skeletal muscle, have been shown to display varying
degrees of myogenic potential. Two of these cell types
that have also been extensively studied in humans are
mesoangioblasts and pericytes, which are both vessel-
associated cells. Mesoangioblasts were first shown to be
of therapeutic value when injected into alpha-
sarcoglycan-null mice and partially correcting the dys-
trophic phenotype [53]. The major advantage these cells
have over satellite cells is their ability to cross blood ves-
sel walls, making systemic delivery far more feasible.
Promising results from animal studies have led to Phase
I clinical trials in DMD patients [54]. A recent study has
revealed the possibility of genetically engineering
mesoangioblasts to carry a human artificial chromosome
(HAC) vector that carries the full-length dystrophin
gene. Both intramuscular and intra-arterial injection of
these modified cells into dystrophin-deficient mdx mice
resulted in the formation of new, dystrophin-expressing
myofibers. These cells were also shown to be able to
contribute to the resident satellite cell population [55].
This study, therefore, encourages the isolation of autolo-
gous mesoangioblasts from DMD patients, followed by
genetic correction and re-injection of these cells into the
same patients. There is a well-established protocol for
isolating mesonagioblasts from human muscle biopsies
[56]. However, as this protocol is technically similar to
the pre-plating technique described earlier, it is less
likely to consistently produce a pure population of cells
than a FACS-based prospective isolation technique. Peri-
cytes isolated from human muscle have been shown to
have in vitro myogenic potential and the ability to give
rise to new dystrophin-positive myofibers when injected.
These cells have been shown to be easily expandable in
culture and amenable to genetic correction (in this case,
transduction of a lentiviral vector carrying a mini-
dystrophin gene) [57].
Additional sources of myogenic cells are embryonic
stem (ES) and induced pluripotent stem (iPS) cells. The
major advantage that these cells have over the other cell
types mentioned in this review is that they can be exten-
sively expanded in culture while maintaining their self-
renewal and pluripotent properties. Induced expression
of PAX7 in both human-derived ES and iPS cells has
been shown to produce myogenic precursors that, when
transplanted via intramuscular injection into dystrophin-
deficient mice, resulted in the sustained formation of human
dystrophin-positive myofibers and even replenishment of
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study were generated from resident fibroblasts. This strategy
therefore has the advantage of generating an unlimited
number of autologous myogenic cells that can be re-
injected into the patient without concern about immune re-
jection. iPS cells offer the additional advantage of being
amenable to genetic correction. A recent study has shown
that fibroblast cells derived from patients with limb-girdle
muscular dystrophy type 2D (LGMD2D) can be converted
to iPS cells by overexpression of the reprogramming fac-
tors OCT3/4, KLF4, SOX2 and cMYC (the so-called
‘Yamanaka factors’). These cells were then used to gene-
rate mesoangioblast-like cells which were subsequently
transduced by lentiviral vectors carrying the SGCA gene
(which is defective in LGMD2D patients) and an inducible
version of MyoD (to enhance myogenic differentiation).
Intramuscular and intraarterial injection of these cells into
immunocompromised SGCA-null mice resulted in a sig-
nificant increase in SGCA+ myofibers and an improve-
ment of the functional properties of the targeted
muscle (tibialis anterior) [59]. However, the risk of tera-
toma formation does warrant caution when considering
these cells for clinical trials.Conclusions
A recent study cemented the satellite cell’s status as the
key contributor to muscle regeneration by showing that,
in mice, Pax7+ cells were solely responsible for muscle
mass recovery following acute injury [60]. Although
these results do not rule out the potential therapeutic
value of other cell types, they do provide further evi-
dence that a satellite cell-based therapy is an area of in-
vestigation worth pursuing. Many pivotal studies on
murine satellite cells have been conducted in the last
decade that have paved the way for similar work that
should be done on human satellite cells. Satellite cells
could be tested alone or in combination with the other
cell types mentioned in this review. The fact that numer-
ous MT clinical trials have been performed means that
many of the methodological problems involved with
human cell therapy have already been addressed and
suggests that new therapies may be expeditiously tested.
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